Global Anti-angiogenic Ophthalmic Agent market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Anti-angiogenic Ophthalmic Agent Market Trends, Growth and Outlook 2025-31

The global Anti-angiogenic Ophthalmic Agent market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue. United States market for Anti-angiogenic Ophthalmic Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Anti-angiogenic Ophthalmic Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Anti-angiogenic Ophthalmic Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Anti-angiogenic Ophthalmic Agent players cover Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Anti-angiogenic Ophthalmic Agent Industry Forecast looks at past sales and reviews total world Anti-angiogenic Ophthalmic Agent sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-angiogenic Ophthalmic Agent sales for 2025 through 2031. With Anti-angiogenic Ophthalmic Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-angiogenic Ophthalmic Agent industry. This Insight Report provides a comprehensive analysis of the global Anti-angiogenic Ophthalmic Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-angiogenic Ophthalmic Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Anti-angiogenic Ophthalmic Agent market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-angiogenic Ophthalmic Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-angiogenic Ophthalmic Agent. This report presents a comprehensive overview, market shares, and growth opportunities of Anti-angiogenic Ophthalmic Agent market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Myopic Choroidal Neovascularization &nbsp;&nbsp;&nbsp; Macular Edema &nbsp;&nbsp;&nbsp; Diabetic Retinopathy &nbsp;&nbsp;&nbsp; Macular Degeneration Segmentation by Application: &nbsp;&nbsp;&nbsp; Retail Pharmacies &nbsp;&nbsp;&nbsp; Online Pharmacies &nbsp;&nbsp;&nbsp; Hospital Pharmacies This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Gilead Sciences, Inc. &nbsp;&nbsp;&nbsp; Eyetech Inc. &nbsp;&nbsp;&nbsp; Becton, Dickinson and Company &nbsp;&nbsp;&nbsp; Regeneron Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; Genentech, Inc. &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Allergan plc &nbsp;&nbsp;&nbsp; Bayer AG &nbsp;&nbsp;&nbsp; Santen Pharmaceutical Co., Ltd. &nbsp;&nbsp;&nbsp; Shanghai Pharmaceuticals &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; Sun Pharma &nbsp;&nbsp;&nbsp; Otsuka Pharmaceutical Co. Ltd &nbsp;&nbsp;&nbsp; Daiichi Sankyo &nbsp;&nbsp;&nbsp; ERC Labs &nbsp;&nbsp;&nbsp; Medicom Health care &nbsp;&nbsp;&nbsp; Implant ophthalmic products GmbH &nbsp;&nbsp;&nbsp; The Geuder Group, MORCHER GmbH &nbsp;&nbsp;&nbsp; Novamedika Key Questions Addressed in this Report What is the 10-year outlook for the global Anti-angiogenic Ophthalmic Agent market? What factors are driving Anti-angiogenic Ophthalmic Agent market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Anti-angiogenic Ophthalmic Agent market opportunities vary by end market size? How does Anti-angiogenic Ophthalmic Agent break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Anti-angiogenic Ophthalmic Agent Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Anti-angiogenic Ophthalmic Agent by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Anti-angiogenic Ophthalmic Agent by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Anti-angiogenic Ophthalmic Agent Segment by Type &nbsp;2.2.1 Myopic Choroidal Neovascularization &nbsp;2.2.2 Macular Edema &nbsp;2.2.3 Diabetic Retinopathy &nbsp;2.2.4 Macular Degeneration &nbsp;2.3 Anti-angiogenic Ophthalmic Agent Sales by Type &nbsp;2.3.1 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Anti-angiogenic Ophthalmic Agent Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Anti-angiogenic Ophthalmic Agent Sale Price by Type (2020-2025) &nbsp;2.4 Anti-angiogenic Ophthalmic Agent Segment by Application &nbsp;2.4.1 Retail Pharmacies &nbsp;2.4.2 Online Pharmacies &nbsp;2.4.3 Hospital Pharmacies &nbsp;2.5 Anti-angiogenic Ophthalmic Agent Sales by Application &nbsp;2.5.1 Global Anti-angiogenic Ophthalmic Agent Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Anti-angiogenic Ophthalmic Agent Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Anti-angiogenic Ophthalmic Agent Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Anti-angiogenic Ophthalmic Agent Breakdown Data by Company &nbsp;3.1.1 Global Anti-angiogenic Ophthalmic Agent Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Anti-angiogenic Ophthalmic Agent Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Company (2020-2025) &nbsp;3.2.2 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Anti-angiogenic Ophthalmic Agent Sale Price by Company &nbsp;3.4 Key Manufacturers Anti-angiogenic Ophthalmic Agent Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Anti-angiogenic Ophthalmic Agent Product Location Distribution &nbsp;3.4.2 Players Anti-angiogenic Ophthalmic Agent Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Anti-angiogenic Ophthalmic Agent by Geographic Region &nbsp;4.1 World Historic Anti-angiogenic Ophthalmic Agent Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Anti-angiogenic Ophthalmic Agent Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Anti-angiogenic Ophthalmic Agent Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Anti-angiogenic Ophthalmic Agent Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Anti-angiogenic Ophthalmic Agent Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Anti-angiogenic Ophthalmic Agent Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Anti-angiogenic Ophthalmic Agent Sales Growth &nbsp;4.4 APAC Anti-angiogenic Ophthalmic Agent Sales Growth &nbsp;4.5 Europe Anti-angiogenic Ophthalmic Agent Sales Growth &nbsp;4.6 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Growth 5 Americas &nbsp;5.1 Americas Anti-angiogenic Ophthalmic Agent Sales by Country &nbsp;5.1.1 Americas Anti-angiogenic Ophthalmic Agent Sales by Country (2020-2025) &nbsp;5.1.2 Americas Anti-angiogenic Ophthalmic Agent Revenue by Country (2020-2025) &nbsp;5.2 Americas Anti-angiogenic Ophthalmic Agent Sales by Type (2020-2025) &nbsp;5.3 Americas Anti-angiogenic Ophthalmic Agent Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Anti-angiogenic Ophthalmic Agent Sales by Region &nbsp;6.1.1 APAC Anti-angiogenic Ophthalmic Agent Sales by Region (2020-2025) &nbsp;6.1.2 APAC Anti-angiogenic Ophthalmic Agent Revenue by Region (2020-2025) &nbsp;6.2 APAC Anti-angiogenic Ophthalmic Agent Sales by Type (2020-2025) &nbsp;6.3 APAC Anti-angiogenic Ophthalmic Agent Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Anti-angiogenic Ophthalmic Agent by Country &nbsp;7.1.1 Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2020-2025) &nbsp;7.1.2 Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2020-2025) &nbsp;7.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2020-2025) &nbsp;7.3 Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent by Country &nbsp;8.1.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Anti-angiogenic Ophthalmic Agent &nbsp;10.3 Manufacturing Process Analysis of Anti-angiogenic Ophthalmic Agent &nbsp;10.4 Industry Chain Structure of Anti-angiogenic Ophthalmic Agent 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Anti-angiogenic Ophthalmic Agent Distributors &nbsp;11.3 Anti-angiogenic Ophthalmic Agent Customer 12 World Forecast Review for Anti-angiogenic Ophthalmic Agent by Geographic Region &nbsp;12.1 Global Anti-angiogenic Ophthalmic Agent Market Size Forecast by Region &nbsp;12.1.1 Global Anti-angiogenic Ophthalmic Agent Forecast by Region (2026-2031) &nbsp;12.1.2 Global Anti-angiogenic Ophthalmic Agent Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Anti-angiogenic Ophthalmic Agent Forecast by Type (2026-2031) &nbsp;12.7 Global Anti-angiogenic Ophthalmic Agent Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Gilead Sciences, Inc. &nbsp;13.1.1 Gilead Sciences, Inc. Company Information &nbsp;13.1.2 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Gilead Sciences, Inc. Main Business Overview &nbsp;13.1.5 Gilead Sciences, Inc. Latest Developments &nbsp;13.2 Eyetech Inc. &nbsp;13.2.1 Eyetech Inc. Company Information &nbsp;13.2.2 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Eyetech Inc. Main Business Overview &nbsp;13.2.5 Eyetech Inc. Latest Developments &nbsp;13.3 Becton, Dickinson and Company &nbsp;13.3.1 Becton, Dickinson and Company Company Information &nbsp;13.3.2 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Becton, Dickinson and Company Main Business Overview &nbsp;13.3.5 Becton, Dickinson and Company Latest Developments &nbsp;13.4 Regeneron Pharmaceuticals, Inc. &nbsp;13.4.1 Regeneron Pharmaceuticals, Inc. Company Information &nbsp;13.4.2 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Regeneron Pharmaceuticals, Inc. Main Business Overview &nbsp;13.4.5 Regeneron Pharmaceuticals, Inc. Latest Developments &nbsp;13.5 Genentech, Inc. &nbsp;13.5.1 Genentech, Inc. Company Information &nbsp;13.5.2 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Genentech, Inc. Main Business Overview &nbsp;13.5.5 Genentech, Inc. Latest Developments &nbsp;13.6 Novartis AG &nbsp;13.6.1 Novartis AG Company Information &nbsp;13.6.2 Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Novartis AG Main Business Overview &nbsp;13.6.5 Novartis AG Latest Developments &nbsp;13.7 Allergan plc &nbsp;13.7.1 Allergan plc Company Information &nbsp;13.7.2 Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Allergan plc Main Business Overview &nbsp;13.7.5 Allergan plc Latest Developments &nbsp;13.8 Bayer AG &nbsp;13.8.1 Bayer AG Company Information &nbsp;13.8.2 Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Bayer AG Main Business Overview &nbsp;13.8.5 Bayer AG Latest Developments &nbsp;13.9 Santen Pharmaceutical Co., Ltd. &nbsp;13.9.1 Santen Pharmaceutical Co., Ltd. Company Information &nbsp;13.9.2 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Santen Pharmaceutical Co., Ltd. Main Business Overview &nbsp;13.9.5 Santen Pharmaceutical Co., Ltd. Latest Developments &nbsp;13.10 Shanghai Pharmaceuticals &nbsp;13.10.1 Shanghai Pharmaceuticals Company Information &nbsp;13.10.2 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Shanghai Pharmaceuticals Main Business Overview &nbsp;13.10.5 Shanghai Pharmaceuticals Latest Developments &nbsp;13.11 Johnson & Johnson &nbsp;13.11.1 Johnson & Johnson Company Information &nbsp;13.11.2 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Johnson & Johnson Main Business Overview &nbsp;13.11.5 Johnson & Johnson Latest Developments &nbsp;13.12 Pfizer &nbsp;13.12.1 Pfizer Company Information &nbsp;13.12.2 Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Pfizer Main Business Overview &nbsp;13.12.5 Pfizer Latest Developments &nbsp;13.13 Sun Pharma &nbsp;13.13.1 Sun Pharma Company Information &nbsp;13.13.2 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Sun Pharma Main Business Overview &nbsp;13.13.5 Sun Pharma Latest Developments &nbsp;13.14 Otsuka Pharmaceutical Co. Ltd &nbsp;13.14.1 Otsuka Pharmaceutical Co. Ltd Company Information &nbsp;13.14.2 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Otsuka Pharmaceutical Co. Ltd Main Business Overview &nbsp;13.14.5 Otsuka Pharmaceutical Co. Ltd Latest Developments &nbsp;13.15 Daiichi Sankyo &nbsp;13.15.1 Daiichi Sankyo Company Information &nbsp;13.15.2 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Daiichi Sankyo Main Business Overview &nbsp;13.15.5 Daiichi Sankyo Latest Developments &nbsp;13.16 ERC Labs &nbsp;13.16.1 ERC Labs Company Information &nbsp;13.16.2 ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 ERC Labs Main Business Overview &nbsp;13.16.5 ERC Labs Latest Developments &nbsp;13.17 Medicom Health care &nbsp;13.17.1 Medicom Health care Company Information &nbsp;13.17.2 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.17.4 Medicom Health care Main Business Overview &nbsp;13.17.5 Medicom Health care Latest Developments &nbsp;13.18 Implant ophthalmic products GmbH &nbsp;13.18.1 Implant ophthalmic products GmbH Company Information &nbsp;13.18.2 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.18.4 Implant ophthalmic products GmbH Main Business Overview &nbsp;13.18.5 Implant ophthalmic products GmbH Latest Developments &nbsp;13.19 The Geuder Group, MORCHER GmbH &nbsp;13.19.1 The Geuder Group, MORCHER GmbH Company Information &nbsp;13.19.2 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.19.4 The Geuder Group, MORCHER GmbH Main Business Overview &nbsp;13.19.5 The Geuder Group, MORCHER GmbH Latest Developments &nbsp;13.20 Novamedika &nbsp;13.20.1 Novamedika Company Information &nbsp;13.20.2 Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolios and Specifications &nbsp;13.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.20.4 Novamedika Main Business Overview &nbsp;13.20.5 Novamedika Latest Developments 14 Research Findings and Conclusion

Report	Global Anti-angiogenic Ophthalmic Agent Market Growth 2025-2031
Selected License	Multi ID: LPI39256

Buyer Information

Order Summary